Difference between revisions of "Dermatofibrosarcoma protuberans"
Jump to navigation
Jump to search
(Created page with "<span id="BackToTop"></span> <div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px;...") |
Warner-admin (talk | contribs) m (Text replacement - "==[https://www.nccn.org/ NCCN]==" to "==NCCN==") |
||
(12 intermediate revisions by 3 users not shown) | |||
Line 3: | Line 3: | ||
[[#top|Back to Top]] | [[#top|Back to Top]] | ||
</div> | </div> | ||
− | {{#lst: | + | {{#lst:Editorial board transclusions|sarcoma}} |
Note: these are regimens tested in subtype-specific populations, please see the '''[[Soft_tissue_sarcoma|main soft tissue sarcoma page]]''' for other regimens. | Note: these are regimens tested in subtype-specific populations, please see the '''[[Soft_tissue_sarcoma|main soft tissue sarcoma page]]''' for other regimens. | ||
{| class="wikitable" style="float:right; margin-right: 5px;" | {| class="wikitable" style="float:right; margin-right: 5px;" | ||
Line 12: | Line 12: | ||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
=Guidelines= | =Guidelines= | ||
− | ==[https://www.nccn.org/ NCCN] | + | '''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.''' |
− | *[https:// | + | ==NCCN== |
+ | *[https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1430 NCCN Guidelines - Dermatofibrosarcoma Protuberans (DFSP)] | ||
+ | **'''2014:''' Bichakjian et al. [https://doi.org/10.6004/jnccn.2014.0081 Dermatofibrosarcoma protuberans, version 1.2014] [https://pubmed.ncbi.nlm.nih.gov/24925197/ PubMed] | ||
+ | **'''2012:''' Miller et al. [https://doi.org/10.6004/Jnccn.2012.0032 Dermatofibrosarcoma protuberans.] [https://pubmed.ncbi.nlm.nih.gov/22393193/ PubMed] | ||
+ | **'''2007:''' Miller et al. [https://doi.org/10.6004/Jnccn.2007.0048 Dermatofibrosarcoma protuberans.] [https://pubmed.ncbi.nlm.nih.gov/17509257/ PubMed] | ||
+ | **'''2004:''' Authors not listed. [https://doi.org/10.6004/Jnccn.2004.0006 Dermatofibrosarcoma protuberans. Clinical practice guidelines in oncology.] [https://pubmed.ncbi.nlm.nih.gov/19777697/ PubMed] | ||
+ | |||
=All lines of therapy= | =All lines of therapy= | ||
==Imatinib monotherapy {{#subobject:d700c4|Regimen=1}}== | ==Imatinib monotherapy {{#subobject:d700c4|Regimen=1}}== | ||
Line 25: | Line 31: | ||
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3040044/ Rutkowski et al. 2010 (SWOG S0345)] | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3040044/ Rutkowski et al. 2010 (SWOG S0345)] | ||
|2005-2006 | |2005-2006 | ||
− | | style="background-color:#ffffbe" |Phase 2, | + | | style="background-color:#ffffbe" |Phase 2, fewer than 20 pts |
|- | |- | ||
|} | |} | ||
Line 42: | Line 48: | ||
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3040044/ Rutkowski et al. 2010 (EORTC 62027)] | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3040044/ Rutkowski et al. 2010 (EORTC 62027)] | ||
|2004-2007 | |2004-2007 | ||
− | | style="background-color:#ffffbe" |Phase 2, | + | | style="background-color:#ffffbe" |Phase 2, fewer than 20 pts (RT) |
|- | |- | ||
|} | |} | ||
Line 51: | Line 57: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # '''EORTC 62027:''' Rutkowski P, Van Glabbeke M, Rankin CJ, Ruka W, Rubin BP, Debiec-Rychter M, Lazar A, Gelderblom H, Sciot R, Lopez-Terrada D, Hohenberger P, van Oosterom AT, Schuetze SM; [[Study_Groups#EORTC|EORTC]] Soft Tissue and Bone Sarcoma Group; [[Study_Groups#SWOG|SWOG]]. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol. 2010 Apr 1;28(10):1772-9. Epub 2010 Mar 1. [https://doi.org/10.1200/JCO.2009.25.7899 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3040044/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/20194851/ PubMed] NCT00085475 | + | # '''EORTC 62027:''' Rutkowski P, Van Glabbeke M, Rankin CJ, Ruka W, Rubin BP, Debiec-Rychter M, Lazar A, Gelderblom H, Sciot R, Lopez-Terrada D, Hohenberger P, van Oosterom AT, Schuetze SM; [[Study_Groups#EORTC|EORTC]] Soft Tissue and Bone Sarcoma Group; [[Study_Groups#SWOG|SWOG]]. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol. 2010 Apr 1;28(10):1772-9. Epub 2010 Mar 1. [https://doi.org/10.1200/JCO.2009.25.7899 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3040044/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/20194851/ PubMed] [https://clinicaltrials.gov/study/NCT00085475 NCT00085475] |
− | # '''SWOG S0345:''' Rutkowski P, Van Glabbeke M, Rankin CJ, Ruka W, Rubin BP, Debiec-Rychter M, Lazar A, Gelderblom H, Sciot R, Lopez-Terrada D, Hohenberger P, van Oosterom AT, Schuetze SM; [[Study_Groups#EORTC|EORTC]] Soft Tissue and Bone Sarcoma Group; [[Study_Groups#SWOG|SWOG]]. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol. 2010 Apr 1;28(10):1772-9. Epub 2010 Mar 1. [https://doi.org/10.1200/JCO.2009.25.7899 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3040044/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/20194851/ PubMed] NCT00084630 | + | # '''SWOG S0345:''' Rutkowski P, Van Glabbeke M, Rankin CJ, Ruka W, Rubin BP, Debiec-Rychter M, Lazar A, Gelderblom H, Sciot R, Lopez-Terrada D, Hohenberger P, van Oosterom AT, Schuetze SM; [[Study_Groups#EORTC|EORTC]] Soft Tissue and Bone Sarcoma Group; [[Study_Groups#SWOG|SWOG]]. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol. 2010 Apr 1;28(10):1772-9. Epub 2010 Mar 1. [https://doi.org/10.1200/JCO.2009.25.7899 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3040044/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/20194851/ PubMed] [https://clinicaltrials.gov/study/NCT00084630 NCT00084630] |
[[Category:Dermatofibrosarcoma protuberans regimens]] | [[Category:Dermatofibrosarcoma protuberans regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
[[Category:Soft tissue sarcomas]] | [[Category:Soft tissue sarcomas]] |
Latest revision as of 11:23, 13 May 2024
Section editor | |
---|---|
Elizabeth J. Davis, MD Vanderbilt University Nashville, TN, USA |
Note: these are regimens tested in subtype-specific populations, please see the main soft tissue sarcoma page for other regimens.
1 regimens on this page
2 variants on this page
|
Guidelines
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
NCCN
- NCCN Guidelines - Dermatofibrosarcoma Protuberans (DFSP)
- 2014: Bichakjian et al. Dermatofibrosarcoma protuberans, version 1.2014 PubMed
- 2012: Miller et al. Dermatofibrosarcoma protuberans. PubMed
- 2007: Miller et al. Dermatofibrosarcoma protuberans. PubMed
- 2004: Authors not listed. Dermatofibrosarcoma protuberans. Clinical practice guidelines in oncology. PubMed
All lines of therapy
Imatinib monotherapy
Regimen variant #1, 400 mg/day
Study | Dates of enrollment | Evidence |
---|---|---|
Rutkowski et al. 2010 (SWOG S0345) | 2005-2006 | Phase 2, fewer than 20 pts |
Regimen variant #2, 800 mg/day
Study | Dates of enrollment | Evidence |
---|---|---|
Rutkowski et al. 2010 (EORTC 62027) | 2004-2007 | Phase 2, fewer than 20 pts (RT) |
Targeted therapy
- Imatinib (Gleevec) 400 mg PO twice per day
Continued indefinitely, unless complete (R0) surgical resection became possible
References
- EORTC 62027: Rutkowski P, Van Glabbeke M, Rankin CJ, Ruka W, Rubin BP, Debiec-Rychter M, Lazar A, Gelderblom H, Sciot R, Lopez-Terrada D, Hohenberger P, van Oosterom AT, Schuetze SM; EORTC Soft Tissue and Bone Sarcoma Group; SWOG. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol. 2010 Apr 1;28(10):1772-9. Epub 2010 Mar 1. link to original article contains dosing details in manuscript link to PMC article PubMed NCT00085475
- SWOG S0345: Rutkowski P, Van Glabbeke M, Rankin CJ, Ruka W, Rubin BP, Debiec-Rychter M, Lazar A, Gelderblom H, Sciot R, Lopez-Terrada D, Hohenberger P, van Oosterom AT, Schuetze SM; EORTC Soft Tissue and Bone Sarcoma Group; SWOG. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol. 2010 Apr 1;28(10):1772-9. Epub 2010 Mar 1. link to original article contains dosing details in manuscript link to PMC article PubMed NCT00084630